Torrent Cash And Equivalents from 2010 to 2024

TORNTPHARM   3,324  121.25  3.79%   
Torrent Pharmaceuticals' Cash And Equivalents is decreasing with slightly volatile movements from year to year. Cash And Equivalents is predicted to flatten to about 324.7 M. For the period between 2010 and 2024, Torrent Pharmaceuticals, Cash And Equivalents quarterly trend regression had mean deviation of  2,761,168,071 and range of 6.1 B. View All Fundamentals
 
Cash And Equivalents  
First Reported
2010-12-31
Previous Quarter
341.8 M
Current Value
324.7 M
Quarterly Volatility
2.9 B
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Torrent Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Torrent Pharmaceuticals' main balance sheet or income statement drivers, such as Depreciation And Amortization of 8.4 B, Interest Expense of 1.8 B or Selling General Administrative of 4.4 B, as well as many indicators such as . Torrent financial statements analysis is a perfect complement when working with Torrent Pharmaceuticals Valuation or Volatility modules.
  
This module can also supplement various Torrent Pharmaceuticals Technical models . Check out the analysis of Torrent Pharmaceuticals Correlation against competitors.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Other Information on Investing in Torrent Stock

Torrent Pharmaceuticals financial ratios help investors to determine whether Torrent Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Torrent with respect to the benefits of owning Torrent Pharmaceuticals security.